MedImmune Completes Cellective Acquisition
MedImmune, Inc. announced that it has completed its acquisition of Cellective Therapeutics, Inc., a private Maryland-based biopharmaceutical company focused on the development of therapeutic monoclonal antibodies targeting B-lymphocyte receptors.
The transaction provides MedImmune with three preclinical-stage programs developing monoclonal antibodies targeting the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important roles in regulating the immune system with potential implications in both cancer and autoimmune diseases.
In September 2005, MedImmune signed a definitive agreement to acquire Cellective Therapeutics, Inc. in a cash transaction that includes an upfront payment and the potential for future milestones, all of which could total up to approximately $160 million if all contingencies are met. Under the terms of the agreement, MedImmune will make milestone payments to Cellective shareholders based upon achieving certain product development and sales goals for Cellective's preclinical antibody programs targeting CD19, CD20 and CD22. MedImmune's relationship with Cellective Therapeutics began in September 2004 when MedImmune Ventures, Inc. participated in Cellective's Series A financing round.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous